nach oben

Erschienen in:

01.03.2013 | Original paper

Serum 25-hydroxyvitamin D and breast cancer in the military: a case–control study utilizing pre-diagnostic serum

verfasst von: Sharif B. Mohr, Edward D. Gorham, John E. Alcaraz, Christopher I. Kane, Caroline A. Macera, J. Kellogg Parsons, Deborah L. Wingard, Ronald Horst, Cedric F. Garland

Erschienen in: Cancer Causes & Control | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective of this study was to ascertain whether a relationship exists between pre-diagnostic serum levels of 25-hydroxyvitamin D (25(OH)D) and risk of breast cancer in young women.

Methods

About 600 incident cases of breast cancer were matched to 600 controls as part of a nested case–control study that utilized pre-diagnostic sera. Logistic regression was used to assess the relationship between serum 25(OH)D concentration and breast cancer risk, controlling for race and age.

Results

According to the conditional logistic regression for all subjects, odds ratios for breast cancer by quintile of serum 25(OH)D from lowest to highest were 1.2, 1.0, 0.9, 1.1, and 1.0 (reference) (p trend = 0.72). After multivariate regression for subjects whose blood had been collected within 90 days preceding diagnosis, odds ratios for breast cancer by quintile of serum 25(OH)D from lowest to highest were 3.3, 1.9, 1.7, 2.6, and 1.0 (reference) (p trend = 0.09).

Conclusions

An inverse association between serum 25(OH)D concentration and risk of breast cancer was not present in the principal analysis, although an inverse association was present in a small subgroup analysis of subjects whose blood had been collected within 90 days preceding diagnosis. Further prospective studies of 25(OH)D and breast cancer risk are needed.

Nur mit Berechtigung zugänglich

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29PubMedCrossRef

Gorham E, Garland C, Garland F (1989) Acid haze air pollution and breast and colon cancer in 20 Canadian cities. Can J Publ Health 80:96–100

Gorham ED, Garland FC, Garland CF (1990) Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 19(4):820–824PubMedCrossRef

Grant WB (2002) An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 94(1):272–281PubMedCrossRef

Garland C, Gorham E, Mohr S, Grant W, Giovannucci E, Lipkin M et al (2007) Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 103(3–5):708–711PubMedCrossRef

Mohr S, Garland C, Gorham E, Grant W, Garland F (2008) Relationship between low ultraviolet B irradiance and higher breast cancer risk in 107 countries. Breast J 14(3):255–260PubMedCrossRef

Grant WB (2012) Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers. J Photochem Photobiol B 101(2):130–136, 3 Nov

Gorham E, Garland F, Garland C (1990) Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 19(4):820–824PubMedCrossRef

Garland C, al. e. (1990) Levels of serum 25-hydroxyvitamin D, 60 individuals aged 60+ years [Graph]. Rancho Bernardo, CA

10.

Garland C, Garland F, Gorham E (1992) Could sunscreens increase melanoma risk? Am J Public Health 82:614–615PubMedCrossRef

11.

Freedman D, Dosemeci M, McGlynn K (2002) Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup Environ Med 59(4):257–262PubMedCrossRef

12.

Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR (2002) Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 30(5):771–777PubMedCrossRef

13.

Garland F, Garland C, Gorham E, Young J Jr (1990) Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 19:614–622PubMedCrossRef

14.

John E, Schwartz G, Dreon D, Koo J (1999) Vitamin D and breast cancer risk: the NHANES I epidemiologic follow-up study, 1971–1975 to 1992. Cancer Epidemiol Biomark Prev 8:399–406

15.

Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC (2002) Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 94(17):1301–1311PubMedCrossRef

16.

Rossi M, McLaughlin JK, Lagiou P, Bosetti C, Talamini R, Lipworth L et al (2009) Vitamin D intake and breast cancer risk: a case-control study in Italy. Ann Oncol 20(2):374–378PubMedCrossRef

17.

Robien K, Cutler GJ, Lazovich D (2007) Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women’s Health Study. Cancer Causes Control 18(7):775–782PubMedCrossRef

18.

Abbas S, Linseisen J, Chang-Claude J (2007) Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. Nutr Cancer 59(1):54–61PubMedCrossRef

19.

Abbas S, Chang-Claude J, Linseisen J (2009) Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer 124(1):250–255PubMedCrossRef

20.

Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D et al (2008) Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer—results of a large case-control study. Carcinogenesis 29(1):93–99PubMedCrossRef

21.

Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC et al (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14(8):1991–1997PubMedCrossRef

22.

Chlebowski R, Johnson K, Kooperberg C et al (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. JNCI 100:1581–1591PubMedCrossRef

23.

Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E et al (2009) Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila) 2(6):598–604CrossRef

24.

Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC et al (2010) Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 19(9):2341–2350PubMedCrossRef

25.

Green AK, Hankinson SE, Bertone-Johnson ER, Tamimi RM (2010) Mammographic density, plasma vitamin D levels and risk of breast cancer in postmenopausal women. Int J Cancer 127(3):667–674PubMedCrossRef

26.

Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG et al (2005) Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 41(8):1164–1169PubMedCrossRef

27.

Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L et al (2009) Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 18(10):2655–2660PubMedCrossRef

28.

Garland C, Comstock G, Garland F, Helsing K, Shaw E, Gorham E (1989) Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 2:1176–1178PubMedCrossRef

29.

Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, Hankinson SE (2007) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 16(4):783–788PubMedCrossRef

30.

Garland C, Gorham E, Garland F (2009) Vitamin D for cancer prevention: global perspective. Ann Epidemiol 19(7):468–483

31.

Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA et al (2008) Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 17(4):889–894PubMedCrossRef

32.

McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL et al (2009) Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res 11(4):R64PubMedCrossRef

33.

Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J (2010) Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study. Int J Cancer Journal international du cancer 127(9):2159–2168, 1 Nov

34.

Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE (2011) Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses’ Health Study II. Breast Cancer Res BCR 13(3):R50

35.

Mohr SB, Gorham ED, Alcaraz JE, Kane CJ, Macera CA, Parsons JK, et al (2011) Serum 25-hydroxyvitamin D and prevention of breast cancer: pooled analysis. Anticancer Res 31(9):2939–2948, Sep

36.

Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H (2012) Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 46(12):2196–2205, Aug

37.

Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al (2012) Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128(6):1414–1424, 15 Mar

38.

Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H (2010) Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treatment 121(2):469–477, Jun

39.

Rubertone MV, Brundage JF (2002) The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health 92(12):1900–1904PubMedCrossRef

40.

Ersfeld DL, Rao DS, Body JJ, Sackrison JL Jr, Miller AB, Parikh N et al (2004) Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 37(10):867–874PubMedCrossRef

41.

Wagner D, Hanwell HE, Vieth R (2009) An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem 42(15):1549–1556PubMedCrossRef

42.

Carter GD, Carter R, Jones J, Berry J (2004) How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem 50(11):2195–2197PubMedCrossRef

43.

Mantel N (1963) Chi square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58:690–700

44.

Bluff JE, Brown NJ, Reed MW, Staton CA (2008) Tissue factor, angiogenesis and tumour progression. Breast Cancer Res BCR 10(2):204

45.

Grant WB (2011) Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level: Implications for meta-analyses and setting vitamin D guidelines. Dermato-Endocrinology 3(3):199–204PubMed

46.

Merck Manual of Diagnosis and Therapy (2003) Breast disorders: cancer. In: Robert S, Porter M (ed). Merck Publishing Group, Whitehouse Station

47.

van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152(6):514–527, 15 Sep

48.

Pandey S, Maheshwari A, Bhattacharya S (2010) The impact of female obesity on the outcome of fertility treatment. J Hum Reprod Sci 3(2):62–67PubMedCrossRef

49.

Gesink Law DC, Maclehose RF, Longnecker MP (2007) Obesity and time to pregnancy. Hum Reprod 22(2):414–420, Feb

50.

Nolte R, Franckowiak SC, Crespo CJ, Andersen RE (2002) U.S. military weight standards: what percentage of U.S. young adults meet the current standards? Am J Med 113(6):486–490PubMedCrossRef

51.

Welsh J (2004) Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 80(6 Suppl):1721S–1724SPubMed

52.

Eisman J, Martin T, MacIntyre I, Mosely J (1979) 1,25-dihydroxyvitamin D3 receptor in breast cancer cells. Lancet 2:1335–1336PubMedCrossRef

53.

Pendas-Franco N, Gonzalez-Sancho JM, Suarez Y, Aguilera O, Steinmeyer A, Gamallo C et al (2007) Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 75(3):193–207PubMedCrossRef

54.

Wang Q, Lee D, Sysounthone V, Chandraratna RAS, Christakos S, Korah R et al (2001) 1,25-dihydroxyvitamin D3 and retinoic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res Treat 67(2):157–168PubMedCrossRef

55.

Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM, Garrett PA et al (1999) Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr 2(3):283–291PubMedCrossRef

56.

Hiatt RA, Krieger N, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N (1998) Prediagnostic serum vitamin D and breast cancer. J Natl Cancer Inst 90(6):461–463PubMedCrossRef

57.

Friedenreich CM (2012) Physical activity and breast cancer: review of the epidemiologic evidence and biologic mechanisms. Recent Results Cancer Res 188:125–139

58.

Anderson LN, Cotterchio M, Kirsh VA, Knight JA (2011) Ultraviolet sunlight exposure during adolescence and adulthood and breast cancer risk: a population-based case-control study among Ontario women. Am J Epidemiol 174(3):293–304, 9 Jun

Titel: Serum 25-hydroxyvitamin D and breast cancer in the military: a case–control study utilizing pre-diagnostic serum
verfasst von: Sharif B. Mohr
Edward D. Gorham
John E. Alcaraz
Christopher I. Kane
Caroline A. Macera
J. Kellogg Parsons
Deborah L. Wingard
Ronald Horst
Cedric F. Garland
Publikationsdatum: 01.03.2013
Verlag: Springer Netherlands
Erschienen in: Cancer Causes & Control / Ausgabe 3/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-012-0140-6

Springer Medizin

Serum 25-hydroxyvitamin D and breast cancer in the military: a case–control study utilizing pre-diagnostic serum